The role of IL-33/ST2L signals in the immune cells

Immunology Letters

Volumn 164, Issue 1, 2015, Pages 11-17

  Lu, Jingli ^a   Kang, Jian ^a   Zhang, Chengliang ^b   Zhang, Xiaojian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

IL 33; Immune cells; SST2; ST2L

Indexed keywords

INTERLEUKIN 1 RECEPTOR RELATED PROTEIN 1; INTERLEUKIN 10; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN;

ALLERGIC CONJUNCTIVITIS; ARTICLE; ATOPIC DERMATITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATION; LIVER FIBROSIS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOID CELL; MACROPHAGE; MAST CELL; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; ANIMAL; CYTOLOGY; GENETICS; IMMUNE SYSTEM; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-33; RECEPTORS, CELL SURFACE;

EID: 84922513949     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.01.008     Document Type: Review

References (97)

1. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., Kastelein R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551-2555.
2. Liu X., Hammel M., He Y., Tainer J.A., Jeng U.S., Zhang L., et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A 2013, 110:14918-14923.
3. Ali S., Huber M., Kollewe C., Bischoff S.C., Falk W., Martin M.U. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007, 104:18660-18665.
4. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
5. Kuroiwa K., Arai T., Okazaki H., Minota S., Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001, 284:1104-1108.
6. Oshikawa K., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., Ohno S., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001, 164:277-281.
7. Tajima S., Oshikawa K., Tominaga S., Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003, 124:1206-1214.
8. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
9. Lunderius-Andersson C., Enoksson M., Nilsson G. Mast cells respond to cell injury through the recognition of IL-33. Front Immunol 2012, 3:82.
10. Oshikawa K., Yanagisawa K., Tominaga S., Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002, 299:18-24.
11. Lohning M., Stroehmann A., Coyle A.J., Grogan J.L., Lin S., Gutierrez-Ramos J.C., et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998, 95:6930-6935.
12. Wang J.X., Kaieda S., Ameri S., Fishgal N., Dwyer D., Dellinger A., et al. IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci U S A 2014, 111:10281-10286.
13. Mirchandani A.S., Salmond R.J., Liew F.Y. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012, 33:389-396.
14. Blom L., Poulsen L.K. IL-1 family members IL-18 and IL-33 upregulate the inflammatory potential of differentiated human Th1 and Th2 cultures. J Immunol 2012, 189:4331-4337.
15. Mayuzumi N., Matsushima H., Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009, 39:3331-3342.
16. Joshi A.D., Oak S.R., Hartigan A.J., Finn W.G., Kunkel S.L., Duffy K.E., et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol 2010, 11:52.
17. Allakhverdi Z., Smith D.E., Comeau M.R., Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007, 179:2051-2054.
18. Hung L.Y., Lewkowich I.P., Dawson L.A., Downey J., Yang Y., Smith D.E., et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci U S A 2013, 110:282-287.
19. Yin H., Li X.Y., Jin X.B., Zhang B.B., Gong Q., Yang H., et al. IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation 2010, 89:1189-1197.
20. Oboki K., Ohno T., Kajiwara N., Arae K., Morita H., Ishii A., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010, 107:18581-18586.
21. Xu D., Jiang H.R., Li Y., Pushparaj P.N., Kurowska-Stolarska M., Leung B.P., et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010, 184:2620-2626.
22. Tjota M.Y., Williams J.W., Lu T., Clay B.S., Byrd T., Hrusch C.L., et al. IL-33-dependent induction of allergic lung inflammation by FcgammaRIII signaling. J Clin Invest 2013, 123:2287-2297.
23. Pushparaj P.N., Li D., Komai-Koma M., Guabiraba R., Alexander J., McSharry C., et al. Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 2013, 140:70-77.
24. Akcay A., Nguyen Q., He Z., Turkmen K., Won Lee D., Hernando A.A., et al. IL-33 exacerbates acute kidney injury. J Am Soc Nephrol 2011, 22:2057-2067.
25. Duan L., Chen J., Zhang H., Yang H., Zhu P., Xiong A., et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 2012, 18:753-761.
26. Schiering C., Krausgruber T., Chomka A., Frohlich A., Adelmann K., Wohlfert E.A., et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014, 513:564-568.
27. Barbour M., Allan D., Xu H., Pei C., Chen M., Niedbala W., et al. IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol 2014, 44:3320-3329.
28. Brunner S.M., Schiechl G., Falk W., Schlitt H.J., Geissler E.K., Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 2011, 24:1027-1039.
29. Sattler S., Ling G.S., Xu D., Hussaarts L., Romaine A., Zhao H., et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun 2014, 50:107-122.
30. Wicher G., Husic E., Nilsson G., Forsberg-Nilsson K. Developmental expression of IL-33 in the mouse brain. Neurosci Lett 2013, 555:171-176.
31. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4T cell populations Annu Rev Immunol 2010, 28:445-489.
32. Meisel C., Bonhagen K., Lohning M., Coyle A.J., Gutierrez-Ramos J.C., Radbruch A., et al. Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001, 166:3143-3150.
33. Piehler D., Grahnert A., Eschke M., Richter T., Kohler G., Stenzel W., et al. T1/ST2 promotes T helper 2 cell activation and polyfunctionality in bronchopulmonary mycosis. Mucosal Immunol 2013, 6:405-414.
34. Townsend M.J., Fallon P.G., Matthews D.J., Jolin H.E., McKenzie A.N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000, 191:1069-1076.
35. Hoshino K., Kashiwamura S., Kuribayashi K., Kodama T., Tsujimura T., Nakanishi K., et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 1999, 190:1541-1548.
36. Guo L., Wei G., Zhu J., Liao W., Leonard W.J., Zhao K., et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A 2009, 106:13463-13468.
37. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R.C., Stolarski B., Garcia C.C., et al. IL-33 induces antigen-specific IL-5(+) T cells and promotes allergic-induced airway inflammation independent of IL-4. Journal of Immunology 2008, 181:4780-4790.
38. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.
39. Seidelin J.B., Coskun M., Kvist P.H., Holm T.L., Holgersen K., Nielsen O.H. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J Gastroenterol 2014, 50:180-190.
40. Zhao A., Morimoto M., Dawson H., Elfrey J.E., Madden K.B., Gause W.C., et al. Immune regulation of protease-activated receptor-1 expression in murine small intestine during Nippostrongylus brasiliensis infection. J Immunol 2005, 175:2563-2569.
41. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R.C., Stolarski B., Garcia C.C., et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181:4780-4790.
42. Yang Z., Sun R., Grinchuk V., Fernandez-Blanco J.A., Notari L., Bohl J.A., et al. IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent. Am J Physiol Gastrointest Liver Physiol 2013, 304:G381-G389.
43. Chan W.L., Pejnovic N., Lee C.A., Al-Ali N.A. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol 2001, 167:1238-1244.
44. Xu D., Chan W.L., Leung B.P., Huang F., Wheeler R., Piedrafita D., et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998, 187:787-794.
45. Gao K., Li X., Zhang L., Bai L., Dong W., Shi G., et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 2013, 335:463-471.
46. Yang Q., Li G., Zhu Y., Liu L., Chen E., Turnquist H., et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol 2011, 41:3351-3360.
47. Bonilla W.V., Frohlich A., Senn K., Kallert S., Fernandez M., Johnson S., et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 2012, 335:984-989.
48. Ngoi S.M., St Rose M.C., Menoret A.M., Smith D.E., Tovey M.G., Adler A.J., et al. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci U S A 2012, 109:10486-10491.
49. Turnquist H.R., Zhao Z., Rosborough B.R., Liu Q., Castellaneta A., Isse K., et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011, 187:4598-4610.
50. Jovanovic I.P., Pejnovic N.N., Radosavljevic G.D., Pantic J.M., Milovanovic M.Z., Arsenijevic N.N., et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2014, 134:1669-1682.
51. Wasserman A., Ben-Shoshan J., Entin-Meer M., Maysel-Auslender S., Guzner-Gur H., Keren G. Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis. Isr Med Assoc J 2012, 14:620-623.
52. Kim H.Y., Chang Y.J., Subramanian S., Lee H.H., Albacker L.A., Matangkasombut P., et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012, 129:216-227. e211-216.
53. Salimi M., Barlow J.L., Saunders S.P., Xue L., Gutowska-Owsiak D., Wang X., et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 2013, 210:2939-2950.
54. Spooner C.J., Lesch J., Yan D., Khan A.A., Abbas A., Ramirez-Carrozzi V., et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat Immunol 2013, 14:1229-1236.
55. Salmond R.J., Mirchandani A.S., Besnard A.G., Bain C.C., Thomson N.C., Liew F.Y. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J Allergy Clin Immunol 2012, 130:1159-1166. e1156.
56. Flaczyk A., Duerr C.U., Shourian M., Lafferty E.I., Fritz J.H., Qureshi S.T. IL-33 signaling regulates innate and adaptive immunity to Cryptococcus neoformans. J Immunol 2013, 191:2503-2513.
57. Shaw J.L., Fakhri S., Citardi M.J., Porter P.C., Corry D.B., Kheradmand F., et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med 2013, 188:432-439.
58. Imai Y., Yasuda K., Sakaguchi Y., Haneda T., Mizutani H., Yoshimoto T., et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A 2013, 110:13921-13926.
59. Brestoff J.R., Kim B.S., Saenz S.A., Stine R.R., Monticelli L.A., Sonnenberg G.F., et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 2014.
60. McHedlidze T., Waldner M., Zopf S., Walker J., Rankin A.L., Schuchmann M., et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013, 39:357-371.
61. Barlow J.L., Peel S., Fox J., Panova V., Hardman C.S., Camelo A., et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 2013, 132:933-941.
62. Iikura M., Suto H., Kajiwara N., Oboki K., Ohno T., Okayama Y., et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007, 87:971-978.
63. Seki K., Sanada S., Kudinova A.Y., Steinhauser M.L., Handa V., Gannon J., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691.
64. Volarevic V., Mitrovic M., Milovanovic M., Zelen I., Nikolic I., Mitrovic S., et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J Hepatol 2012, 56:26-33.
65. Ho L.H., Ohno T., Oboki K., Kajiwara N., Suto H., Iikura M., et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007, 82:1481-1490.
66. Silver M.R., Margulis A., Wood N., Goldman S.J., Kasaian M., Chaudhary D. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 2010, 59:207-218.
67. Junttila I.S., Watson C., Kummola L., Chen X., Hu-Li J., Guo L., et al. Efficient cytokine-induced IL-13 production by mast cells requires both IL-33 and IL-3. J Allergy Clin Immunol 2013, 132:704-712. e710.
68. Andrade M.V., Iwaki S., Ropert C., Gazzinelli R.T., Cunha-Melo J.R., Beaven M.A. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol 2011, 41:760-772.
69. Cho K.A., Suh J.W., Sohn J.H., Park J.W., Lee H., Kang J.L., et al. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol 2012, 302:L429-L440.
70. Hsu C.L., Neilsen C.V., Bryce P.J. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 2010, 5:e11944.
71. Hsu C.L., Bryce P.J. Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway. J Immunol 2012, 189:3421-3429.
72. Pushparaj P.N., Tay H.K., H'Ng S.C., Pitman N., Xu D., McKenzie A., et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 2009, 106:9773-9778.
73. Lefrancais E., Duval A., Mirey E., Roga S., Espinosa E., Cayrol C., et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 2014, 111:15502-15507.
74. Roy A., Ganesh G., Sippola H., Bolin S., Sawesi O., Dagalv A., et al. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem 2014, 289:237-250.
75. Waern I., Lundequist A., Pejler G., Wernersson S. Mast cell chymase modulates IL-33 levels and controls allergic sensitization in dust-mite induced airway inflammation. Mucosal Immunol 2013, 6:911-920.
76. Su Z., Lin J., Lu F., Zhang X., Zhang L., Gandhi N.B., et al. Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. Mucosal Immunol 2013, 6:921-930.
77. Yanagawa Y., Matsumoto M., Togashi H. Adrenoceptor-mediated enhancement of interleukin-33 production by dendritic cells. Brain Behav Immun 2011, 25:1427-1433.
78. Williams J.W., Tjota M.Y., Clay B.S., Vander Lugt B., Bandukwala H.S., Hrusch C.L., et al. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun 2013, 4:2990.
79. Bajana S., Roach K., Turner S., Paul J., Kovats S. IRF4 promotes cutaneous dendritic cell migration to lymph nodes during homeostasis and inflammation. J Immunol 2012, 189:3368-3377.
80. Tjota M.Y., Hrusch C.L., Blaine K.M., Williams J.W., Barrett N.A., Sperling A.I. Signaling through FcRgamma-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses. J Allergy Clin Immunol 2014, 134:706-713. e708.
81. Rank M.A., Kobayashi T., Kozaki H., Bartemes K.R., Squillace D.L., Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009, 123:1047-1054.
82. Turnquist H.R., Sumpter T.L., Tsung A., Zahorchak A.F., Nakao A., Nau G.J., et al. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol 2008, 181:62-72.
83. Besnard A.G., Togbe D., Guillou N., Erard F., Quesniaux V., Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol 2011, 41:1675-1686.
84. Rincon M., Anguita J., Nakamura T., Fikrig E., Flavell R.A. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997, 185:461-469.
85. Homey B., Zlotnik A. Chemokines in allergy. Curr Opin Immunol 1999, 11:626-634.
86. Chu D.K., Llop-Guevara A., Walker T.D., Flader K., Goncharova S., Boudreau J.E., et al. IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J Allergy Clin Immunol 2013, 131:187-200. e181-188.
87. Murakami-Satsutani N., Ito T., Nakanishi T., Inagaki N., Tanaka A., Vien P.T., et al. IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. Allergol Int 2014, 63:443-455.
88. Matta B.M., Lott J.M., Mathews L.R., Liu Q., Rosborough B.R., Blazar B.R., et al. IL-33 is an unconventional alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T Cells. J Immunol 2014, 193:4010-4020.
89. Espinassous Q., Garcia-de-Paco E., Garcia-Verdugo I., Synguelakis M., von Aulock S., Sallenave J.M., et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009, 183:1446-1455.
90. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009, 183:6469-6477.
91. Wills-Karp M., Rani R., Dienger K., Lewkowich I., Fox J.G., Perkins C., et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med 2012, 209:607-622.
92. Chang Y.J., Kim H.Y., Albacker L.A., Baumgarth N., McKenzie A.N., Smith D.E., et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011, 12:631-638.
93. Komai-Koma M., Gilchrist D.S., McKenzie A.N., Goodyear C.S., Xu D., Liew F.Y. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol 2011, 186:2584-2591.
94. Attanavanich K., Kearney J.F. Marginal zone, but not follicular B cells, are potent activators of naive CD4T cells. J Immunol 2004, 172:803-811.
95. Oliver A.M., Martin F., Kearney J.F. IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol 1999, 162:7198-7207.
96. Rosser E.C., Oleinika K., Tonon S., Doyle R., Bosma A., Carter N.A., et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med 2014, 20:1334-1339.
97. Lloyd C.M. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol 2010, 22:800-806.